Pafolacianine, also known as OTL38, is a novel fluorescent imaging agent that has shown great promise in the field of medical imaging. This drug is used in conjunction with near-infrared imaging technology to help surgeons visualize and identify cancerous tissues during surgery.

Pafolacianine works by binding to specific receptors that are overexpressed in cancer cells, allowing for clear differentiation between healthy and diseased tissue. This targeted approach helps surgeons to more accurately remove cancerous tissue while minimizing damage to surrounding healthy tissue.

Clinical studies have shown that the use of Pafolacianine during surgery can improve the accuracy of tumor removal and reduce the likelihood of cancer recurrence. This can lead to better outcomes for patients and a higher likelihood of successful treatment.

As with any medication, there may be some potential side effects associated with the use of Pafolacianine. These can include mild allergic reactions, nausea, or skin irritation at the injection site. It is important for patients to discuss any concerns or potential risks with their healthcare provider before undergoing treatment with Pafolacianine.

Overall, Pafolacianine represents a significant advancement in the field of medical imaging and cancer treatment. Its ability to improve surgical accuracy and outcomes for patients makes it a valuable tool in the fight against cancer. If you or a loved one are facing cancer surgery, be sure to ask your healthcare provider about the potential benefits of using Pafolacianine as part of your treatment plan.